Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy

Allergy and Asthma Proceedings

Volumn 37, Issue 1, 2016, Pages 50-56

  Larenas Linnemann, Désirée E ^a,b   Mösges, Ralph ^a,b  

^a LIVER RESEARCH UNIT   (Mexico)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POLLEN EXTRACT; ALLERGEN;

ARTICLE; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DOSE RESPONSE; DRUG MANUFACTURE; HUMAN; MAINTENANCE DRUG DOSE; PHLEUM PRATENSE; RAGWEED POLLEN; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; ANIMAL; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; POLLEN; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

ALLERGENS; ANIMALS; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; POLLEN; SUBLINGUAL IMMUNOTHERAPY;

EID: 85010873290     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2016.37.3907     Document Type: Article

References (32)

1. Cox L. Sublingual immunotherapy for aeroallergens: Status in the United States. Allergy Asthma Proc 35: 34-42, 2014.
2. Tucker MH, and Tankersley MS Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol 101: 419-425, 2008.
3. Sikora JM, Tankersley MS, and ACAAI Immunotherapy and Diagnostics Committee. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey. Ann Allergy Asthma Immunol 110: 194-197.e4, 2013.
4. Baena-Cagnani CE, Larenas Linnemann D, Gomez M, et al. Allergy training and immunotherapy in Latin America: Results of a regional overview. Ann Allergy Asthma Immunol 111: 415-419.e1, 2013.
5. Larenas-Linnemann D, and Cox LS European allergen extract units and potency: Review of available information. Ann Allergy Asthma Immunol 100: 137-145, 2008.
6. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117: 802-809, 2006.
7. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 120: 1338-1345, 2007.
8. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grasspollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 123: 160-166.e3, 2009.
9. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 123: 167-173.e7, 2009.
10. Tabatabaian F, and Casale TB Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT). Allergy Asthma Proc 36: 100-104, 2015.
11. Larenas Linnemann DE, and Blaiss MS Selection of patients for sublingual versus subcutaneous immunotherapy. Immunotherapy 6: 871-884, 2014.
12. Stallergenes. H1 2014 revenues and results 2014 (updated July 24, 2014), 1-20. Available online at http://www.stallergenes.com/uploads/tx-stlgnfinance/H1-2014-presentation-24-07-14-2-.pdf; accessed March 8, 2015.
13. ALK-Abelló AS. Financial reporting: Latest full year accounts, 2014. Available online at http://ir.alk-abello.com/financials.cfm; accessed March 8, 2015.
14. Larenas-Linnemann D, Esch R, Plunkett G, et al. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Ann Allergy Asthma Immunol 107: 448-458.e3, 2011.
15. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 127(1 Suppl): S1-S55, 2011.
16. Valovirta E, Jacobsen L, Ljorring C, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 61: 1177-1183, 2006.
17. van Ree R, Chapman MD, Ferreira F, et al. The CREATE project: Development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 63: 310-326, 2008.
18. Skoner DP, Blaiss MS, Dykewicz MS, et al. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: Patients' experience with allergen immunotherapy. Allergy Asthma Proc 35: 219-226, 2014.
19. ALK-Abelló. Company release No 6/2012: ALK expands in France and introduces new, improved SLIT product 2012. Available online at http://files.shareholder.com/downloads/ALKB/572963267x0x551279/44E55ADA-B617-4A03-B1CA-4FEEBDEC8338/FM-06-12UK-08032012.pdf; Accessed August 14, 2015.
20. Moreno Benitez F, Espinazo Romeu M, Letran Camacho A, et al. Variation in allergen content in sublingual allergen immunotherapy (SLIT) with house dust mites (HDM). Allergy 2015 July 17. [Epub ahead of print]
21. Sander I, Fleischer C, Meurer U, et al. Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy 64: 1486-1492, 2009.
22. Rossi R, Monasterolo G, Passalacqua G. The biological potency of different extracts for sublingual immunotherapy assessed by skin prick tests. Eur Ann Allergy Clin Immunol 42: 112-114, 2010.
23. Park KH, Son M, Chen S, et al. In vitro evaluation of allergen potencies of commercial house dust mite sublingual immunotherapy reagents. Allergy Asthma Immunol Res 7: 124-129, 2015.
24. Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 69: 1181-1188, 2014.
25. Bozek A, Ignasiak B, Filipowska B, and Jarzab J. House dust mite sublingual immunotherapy: A double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy 43: 242-248, 2013.
26. Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 133: 1608-1614.e6, 2014
27. Radulovic S, Wilson D, Calderon M, and Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66: 740-752, 2011.
28. Nelson HS, Oppenheimer J, Vatsia GA, and Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 92: 229-236, 1993.
29. Amar SM, Harbeck RJ, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 124: 150-156.e1-5, 2009.
30. Allam JP, Wurtzen PA, Reinartz M, et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 126: 638-645.e1, 2010.
31. Kildsgaard J, Brimnes J, Jacobi H, and Lund K. Sublingual immunotherapy in sensitized mice. Ann Allergy Asthma Immunol 98: 366-372, 2007.
32. Razafindratsita A, Saint-Lu N, Mascarell L, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 120: 278-285, 2007.